GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial) Oral Insulin Therapy for Prevention of Autoimmune Diabetes Prevention of diabetes in very young children (age 4 to 7 month) at high genetic risk for type 1 diabetes with oral insulin therapy
Sonstige - Therapieart: andere